UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2008
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 0-26224 51-0317849
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation or organization) Identification No.)
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On June 6, 2008, Integra LifeSciences Holdings Corporation (the "Company")
received formal notice from The NASDAQ Stock Market LLC ("NASDAQ") that,
following the filing of the Company's Quarterly Report on Form 10-Q for the
period ended March 31, 2008 with the Securities and Exchange Commission, the
Company satisfies all requirements for continued listing on The NASDAQ Global
Market and that it determined to continue the listing of the Company's
securities on NASDAQ.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
99.1 Press release, dated June 6, 2008, issued by Integra LifeSciences
Holdings Corporation
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
Date: June 6, 2008 By: /s/ John B. Henneman, III
---------------------------
John B. Henneman, III
Executive Vice President,
Finance and Administration,
and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ---------- -----------
99.1 Press Release, dated June 6, 2008, issued by Integra LifeSciences
Holdings Corporation.
Exhibit 99.1
News Release
Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III Kathryn Lamping
Executive Vice President Assistant General Counsel
Finance and Administration (609) 936-2276
and Chief Financial Officer kathryn.lamping@Integra-LS.com
(609) 936-2481
jhenneman@Integra-LS.com
Integra LifeSciences Receives NASDAQ Notice of Compliance
PLAINSBORO, N.J., June 6, 2008 (PRIME NEWSWIRE) -- Integra LifeSciences Holdings
Corporation (Nasdaq: IART) today announced that The NASDAQ Stock Market has
formally notified the Company that, following the filing of the Company's
Quarterly Report on Form 10-Q for the period ended March 31, 2008 with the
Securities and Exchange Commission, the Company satisfies all requirements for
continued listing on The NASDAQ Global Market and that it has determined to
continue the listing of the Company's securities on NASDAQ.
"We are pleased with NASDAQ's decision," said Stuart Essig, Integra's President
and Chief Executive Officer. "We look forward to a continued positive working
relationship with The NASDAQ Stock Market."
Integra LifeSciences Holdings Corporation, a world leader in regenerative
medicine, is dedicated to improving the quality of life for patients through the
development, manufacturing, and marketing of cost-effective surgical implants
and medical instruments. Our products, used primarily in neurosurgery, extremity
reconstruction, orthopedics and general surgery, are used to treat millions of
patients every year. Integra's headquarters are in Plainsboro, New Jersey, and
we have research and manufacturing facilities throughout the world. Please visit
our website at (http://www.Integra-LS.com).
IART-G
Source: Integra LifeSciences Holdings Corporation